Skip to main content
Sign In

Anschutz Medical Campus

University of Colorado Denver
​​​​​​​​
 

Research

The CU Anschutz Medical Campus is a nationally recognized leader in the creation of new knowledge and innovative approaches to improving human health. With sponsored research awards totaling more than $400 million annually, CU Anschutz researchers collaborate with partner and affiliate hospitals, clinics and centers to bring research from the bench to the patient’s bedside.

Innov​a​tion

The CU Anschutz tradition of innovation has created several groundbreaking achievements, including the first liver transplant in the world, the first vaccine for shingles, and the first to use human cell cloning to study genetics and cancer.

Disc​​overy

Discoveries on the Anschutz Medical Campus have led to new medical devices, pharmaceuticals, diagnostic methods, treatment of debilitating conditions and improved quality of life for patients and consumers worldwide. Since 2002, CU Anschutz technology has led to the filing of 1,300 patent applications and the formation of 53 new companies, funded by more than $914 million in venture capital and public and private equity investment and grants. ​​​​​​

Research Resources

Search our researcher database and learn about our areas of research expertise. Get information about our labs, facilities and clinical trials. Read about our new Good Manufacturing Practice facility for cell bio-manufacturing.

Learn more

Future vaccine for type 1 diabetes?

Oral insulin lays groundwork for vaccine for type 1 diabetes
Children at risk for type 1 diabetes, who were given daily doses of oral insulin, developed a protective immune response to the disease that researchers with the Barbara Davis Center for Childhood Diabetes at the University of Colorado Anschutz Medical Campus say could possibly lay the groundwork for a vaccine against the chronic illness.
 
"This is the first time we have seen a healthful immune response from any therapy used in children who are at a high risk of type 1 diabetes,” said Georgeanna Klingensmith, MD, professor of pediatrics at the University of Colorado School of Medicine at CU Anschutz, who led the U.S. side of the research. “The results showed that it was safe and none of the children developed diabetes, insulin antibodies or hypoglycemia.”

Learn more